Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981911 | 0.84 | ABL1 (0.42) | TSHRCA1CA2CA12CA9 | |
| SCHEMBL11067163 | 0.83 | CHRNA7 (0.47) | BAZ2BBAZ2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL2411311 | 0.73 | NPSR1 (0.44) | TSHRMAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL11918298 | 0.73 | TSHR (0.41) | BAZ2BBAZ2ATSHRMAPK1CYP4F2 | |
| SCHEMBL235046 | 0.71 | TSHR (0.60) | BAZ2BBAZ2ATSHRMAPK1CYP4F2 | |
| SCHEMBL8659593 | 0.71 | TSHR (0.46) | BAZ2BBAZ2ATSHRMAPK1CA1 | |
| SCHEMBL12458001 | 0.71 | TSHR (0.59) | TSHRCA1CA2CA12CA9 | |
| SCHEMBL549144 | 0.70 | MAPK1 (0.54) | BAZ2BBAZ2ATSHRMAPK1CYP4F2 | |
| SCHEMBL11225504 | 0.70 | CYP4F2 (0.67) | BAZ2BBAZ2ATSHRMAPK1CYP4F2 | |
| SCHEMBL236240 | 0.70 | CYP4F2 (0.57) | BAZ2BBAZ2ATSHRMAPK1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756042-B1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| CN-1950333-A | Substituted methyl aryl or heteroaryl amide compounds | PFIZER (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1756042-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| WO-2005105732-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | PTGER1, PTGER2, PTGER3 | BAZ2B 928/4885BAZ2A 692/4885TSHR 1600/4885 |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PTGER1, PTGER2, PTGER3 | BAZ2B 928/4885BAZ2A 692/4885TSHR 1600/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | BAZ2B 3607/4885BAZ2A 3683/4885TSHR 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.